Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial
Back to article page
OriginalPaper|Updated:2021-08-27
|
Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial
Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial
中国结合医学杂志(英文版)2014年20卷第12期 页码:949-954
Affiliations:
1. Department of Traditional Chinese Medicine, Zhongshan Hospital, Xiamen University,Fujian Province,Xiamen,China
2. Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine,Fuzhou,China
Author bio:
Funds:
Supported by the Foundation of Science and Technology Department of Xiamen (No. 3502Z20084014), the Foundation of Key Projects from Science and Technology Department of Fujian Province (No. 2012D064), and the Foundation of Traditional Chinese Medicine of Fujian Province (No. wst201208)
Huang, Yp., Wen, Yh., Wu, Gh. et al. Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial., Chin. J. Integr. Med. 20, 949–954 (2014). https://doi.org/10.1007/s11655-014-2021-1
Yuan-peng Huang, Yan-hui Wen, Geng-hui Wu, et al. Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2014,20(12):949-954.
Huang, Yp., Wen, Yh., Wu, Gh. et al. Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial., Chin. J. Integr. Med. 20, 949–954 (2014). https://doi.org/10.1007/s11655-014-2021-1DOI:
Yuan-peng Huang, Yan-hui Wen, Geng-hui Wu, et al. Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial[J]. Chinese Journal of Integrative Medicine, 2014,20(12):949-954. DOI: 10.1007/s11655-014-2021-1.
Clinical study on Kangquan Recipe (康泉方) for benign prostatic hyperplasia patients: A randomized controlled trial
摘要
To observe the effectiveness and safety of Kangquan Recipe (康泉方
KQR) for benign prostatic hyperplasia (BPH) patients. One hundred and six BPH patients were randomly assigned to the treatment group (53 cases) and the control group (53 cases) according to a random number table. The treatment group was given KQR orally; the control group was given cernilton orally. After 24-week treatment
the clinical effect and safety were evaluated using the International Prostatic Symptom Score (I-PSS)
quality of life (QOL)
maximum flow rate (Qmax)
average flow rate (Qave)
residual urine volume (RUV)
total prostatic volume (TPV)
etc. After treatment
the score of I-PSS was decreased from 16.9±5.6 to 12.5±4.6 in the treatment group
significantly lower compared with the control group; the levels of Qmax and Qave were from 10.9±3.5 to 15.6±4.5 and 5.4±2.1 to 7.3±2.5 (mL/s) in the treatment group
significantly higher compared with the control group; the levels of RUV and TPV were from 70.8±28.2 to 35.2±21.8 and 37.2±16.9 to 30.1±10.8 (mL) in the treatment group
significantly lower compared with the control group (all P<0.05). The incidence rate of adverse reaction was similar between the two groups (P>0.05). KQR is effective and safe for the treatment of BPH.
Abstract
To observe the effectiveness and safety of Kangquan Recipe (康泉方
KQR) for benign prostatic hyperplasia (BPH) patients. One hundred and six BPH patients were randomly assigned to the treatment group (53 cases) and the control group (53 cases) according to a random number table. The treatment group was given KQR orally; the control group was given cernilton orally. After 24-week treatment
the clinical effect and safety were evaluated using the International Prostatic Symptom Score (I-PSS)
quality of life (QOL)
maximum flow rate (Qmax)
average flow rate (Qave)
residual urine volume (RUV)
total prostatic volume (TPV)
etc. After treatment
the score of I-PSS was decreased from 16.9±5.6 to 12.5±4.6 in the treatment group
significantly lower compared with the control group; the levels of Qmax and Qave were from 10.9±3.5 to 15.6±4.5 and 5.4±2.1 to 7.3±2.5 (mL/s) in the treatment group
significantly higher compared with the control group; the levels of RUV and TPV were from 70.8±28.2 to 35.2±21.8 and 37.2±16.9 to 30.1±10.8 (mL) in the treatment group
significantly lower compared with the control group (all P<0.05). The incidence rate of adverse reaction was similar between the two groups (P>0.05). KQR is effective and safe for the treatment of BPH.
Ministry of Health, P. R. China. Guidance on principle of pre-clinical research on new drug. Beijing: People’s Medical Publishing House; 1993:101–103.
Paolone DR. Benign prostatic hyperplasia. Clin Geriatr Med 2010;26:223–239.
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. Urology 2003;170:530–547.
Huang YP, Wu JF. On relation of collaterals diseases in TCM and benign prostatic hyperplasia. China J Tradit Chin Med Pharm (Chin) 2006;21:45–46.
Yang Y, Gu FL. The opinion recommended by the fifth session of the International Advisory Committee on benign prostatic hyperplasia in the International Scientific Committee: the evaluation and treatment of elderly men with lower urinary tract symptoms. Chin J Urol (Chin) 2001;22:564–570.
Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011;95:87–100.
Huang YP, Du J, Hong ZF, Chen ZQ, Zhao JY, Li TJ, et al. Effect of Kangquan Recipe on apoptosis regulatory genes bax and bcl-2mRNA in prostate of rats. Chin J Integr Tradit West Med (Chin) 2007;27:711–714.
Huang YP, Du J, Hong ZF, Chen ZQ, Zhao JY, Li TJ, et al. Effect of Kangquan Recipe on basic fibroblast growth factor in prostate of rats. Chin J Integr tradit West Med (Chin) 2008;28:711–714.
Huang YP, Du J, Hong ZF, Chen ZQ, Wu JF, Zhao JY, et al. Effects of Kangquan Recipe on sex steroids and cell proliferation in rats with benign prostatic hyperplasia. Chin J Integr Med 2009;15:268–272.
Hong ZF, Lin JM, Zhong XY, Li Y, Zhou JH, Xu W. et al. Qianliening Capsule inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis. Chin J Integr Med 2012;18:824–830
Li YF, Tang LP, He RR, Xu Z, He QQ, Xiang FJ, et al. Anthocyanins extract from bilberry enhances the therapeutic effect of pollen of Brassica napus L. on stress-provoked benign prostatic hyperplasia in restrained mice. J Functi Foods 2013;5:1357–1365.